…do regulators and for-profit actors think about mysticism?
For a regulating body like the FDA, researchers aiming to put a psychedelic drug and treatment through the clinical research pipeline only need to prove two things: that the drug (and its associated protocols) are safe, and that they work successfully at treating the indication they’re after.
While multiple psychedelic substances are currently undergoing dozens of clinical trials with the aims of receiving approval for their use in psychiatric treatment, the safety and efficacy of these substances receives far more attention than the contents of the experiences they induce. The FDA has no particular interest in what happens in the mind of a patient experiencing a psychedelic trip, as long as their condition improves without substantial side effects.
Original Article (Forbes):
Is mysticism becoming a problem for psychedelic medicine?
Artwork Fair Use: Dnu72
